NCT03882749Unknown不适用
A Multicenter Observational Study on the Use of Delivra-Celecoxib 8% Cream on Pain Experienced by Patients With Osteoarthritis of the Knees
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 45
- 试验地点
- 3
- 主要终点
- WOMAC
研究概览
简要总结
The observation of the clinical use of the Delivra Celecoxib cream (8%) in the treatment of osteoarthritis of the knee. Observations will be made over 12 weeks of treatment. Evaluations include: pain, functionality and patients global assessment of disease. Patients will self administer treatment as prescribed.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 30 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Patients with primary osteoarthritis (with radiological evidence) of the knees who have been prescribed Del-Cel.
- •On stable pain therapy with an oral or topical NSAID or acetaminophen.
- •Able to read and understand English to answer pain assessment questions independently.
- •Willing and able to fulfill the requirements of the study, including complete scheduled follow-up phone visits.
排除标准
- •Inability to adequately read and understand English as required to complete study assessments and comply with the protocol.
- •Current recreational or medicinal use of cannabis within 4 weeks of study initiation.
- •Participants with a lifetime history of cannabis use disorder or other substance use disorders (except tobacco use disorder) will be excluded.
- •Participants with a lifetime history of daily cannabis use will be excluded.
- •Dose changes of concomitant medication will not be permitted during the study period.
- •Pregnant women, lactating women, and women of childbearing potential who are not using medically accepted forms of contraception (e.g., IUD, oral contraceptives, barrier devices, condoms and foam, or implanted progesterone rods stabilized for at least 3 months), or women who are planning on becoming pregnant.
- •Diagnosis of any of the following mental disorders as defined by the DSM-5: a lifetime history of schizophrenia or any other psychosis, organic medical disorders, bipolar disorder. Entry of patients with obsessive compulsive disorder or post- traumatic stress disorder will be permitted if the anxiety disorder is judged to be the predominant disorder, in order to increase accrual of a clinically relevant sample.
- •Major depression will be allowed if not severe (Montgomery Åsberg Depression Rating Scale-MADRS27≥ 25). Patients with significant suicidal ideation (MADRS item 10 score > 3) or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention.
- •Participants with a family history of schizophrenia spectrum or bipolar disorder will be excluded.
- •Participants who have a history of adverse reactions to cannabis will be excluded.
- •Known allergy to any of the ingredients in the Delivra base.
- •Use of Rimonabant (SR141716) within three weeks of enrollment and/or planned use for the duration of the study participation[27].
- •Use of 5-HT1A receptor antagonists (SSRI inhibitors) within three weeks of enrollment and/or planned use for the duration of the study participation, e.g.: Pindolol, Lecozotan, Brexpiprazole, etc.
结局指标
主要结局
WOMAC
时间窗: over 12 weeks
Subjects will describe pain and functionality status using a validated likert assessment .
11-Point Numerical Rating Scale Pain Index
时间窗: over 12 weeks
Subjects will rate he pain that they experience from 0-no pain to 10-worst pain inmmaginable
次要结局
- Adverse event reporting(over 12 weeks)
研究者
研究点 (3)
Loading locations...
相似试验
终止
不适用
Delivra-Celecoxib 8% Cream and OsteoarthritisOsteoarthritis, KneeNCT03698916Credit Valley Rheumatology6
已完成
4 期
The Study to Evaluate Efficacy and Safety of Celecoxib Capsule in Hand Osteoarthritis PatientsOsteoarthritis HandNCT03067194Chong Kun Dang Pharmaceutical117
已完成
3 期
Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)OsteoarthritisNCT00542087Organon and Co516
终止
4 期
Celebrex Total Knee Arthroplasty StudyPainOsteoarthritisNCT00359151Pfizer's Upjohn has merged with Mylan to form Viatris Inc.22
已完成
4 期
Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe)Osteoarthritis, KneeNCT00630929Pfizer's Upjohn has merged with Mylan to form Viatris Inc.388